Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.69 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29441818 | 0.96 | SLC6A4 (0.67) | SLC6A4HTR1A | |
| SCHEMBL3103671 | 0.96 | SLC6A4 (0.67) | SLC6A4HTR1A | |
| SCHEMBL8136598 | 0.91 | SLC6A4 (0.64) | SLC6A4HTR2C | |
| SCHEMBL5234124 | 0.85 | SLC6A4 (0.69) | SLC6A4HTR1AMPO | |
| SCHEMBL5791054 | 0.85 | SLC6A4 (0.69) | SLC6A4HTR1AMPO | |
| SCHEMBL3103741 | 0.85 | SLC6A4 (0.73) | SLC6A4HTR1A | |
| SCHEMBL30320095 | 0.85 | SLC6A4 (0.69) | SLC6A4HTR1AMPO | |
| SCHEMBL6879916 | 0.85 | SLC6A4 (0.69) | SLC6A4HTR1AMPO | |
| SCHEMBL8255694 | 0.85 | SLC6A4 (0.69) | SLC6A4HTR1AMPO | |
| SCHEMBL30468389 | 0.85 | SLC6A4 (0.69) | SLC6A4HTR1AMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110511174-B | Indolylalkyl piperazine compound and application thereof | 复旦大学 | 2023-03-28 | — | — | CN | disclosed |
| EP-3027607-B1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| CN-110511174-A | A kind of indolyl piperazine compounds and its application | UNIV FUDAN | 2019-11-29 | — | — | CN | disclosed |
| CN-106279153-B | Substituted benzazolyl compounds and its application method and purposes | 广东东阳光药业有限公司 | 2019-08-16 | — | — | CN | disclosed |
| US-10316025-B2 | Substituted piperazine compounds and methods of use and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-06-11 | — | — | US | disclosed |
| CN-106795143-B | Substituted benzazolyl compounds and its application method and purposes | 广东东阳光药业有限公司 | 2019-05-24 | — | — | CN | disclosed |
| CN-104276993-B | Indole derivatives and its application on drug | 广东东阳光药业有限公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-106243088-B | Substituted diethylenediamine compound and its application method and purposes | 广东东阳光药业有限公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-104337812-B | Substituted heteroaryl compound and its application method and purposes | 广东东阳光药业有限公司 | 2018-09-14 | — | — | CN | disclosed |
| CN-105085482-B | Substituted diethylenediamine compound and its application method and purposes | 广东东阳光药业有限公司 | 2018-08-10 | — | — | CN | disclosed |
| WO-2006061379-A1 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-06-15 | — | — | WO | disclosed |
| EP-0644187-B1 | Antimigraine cyclobutenedione derivatives of tryptamines | BRISTOL MYERS SQUIBB CO (US) | 1998-07-01 | — | — | EP | disclosed |
| US-5521188-A | Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-05-28 | — | — | US | disclosed |
| US-5434154-A | Serotonin agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0645385-A1 | Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines | Bristol-Myers Squibb Company (US) | 1995-03-29 | — | — | EP | disclosed |
| EP-0644187-A1 | Antimigraine cyclobutenedione derivatives of tryptamines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-03-22 | — | — | EP | disclosed |
| US-5382592-A | Antimigraine cyclobutenedione derivatives of tryptamines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-01-17 | — | — | US | disclosed |
| CN-1085556-A | The 4-pyrimidyl and the pyridinyl derivatives of the indol-3-yl alkylpiperazine of anti-migraine | BRISTOL MYERS SQUIBB CO (US) | 1994-04-20 | — | — | CN | disclosed |
| US-5300506-A | Indole-3-alkyl derivatives of alkoxypyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0548813-A1 | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines | Bristol-Myers Squibb Company (US) | 1993-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316025-B2 | Substituted piperazine compounds and methods of use and use thereof | HTR5A, HTR2C, TPH1 | SLC6A4 14/4885HTR1A 8/4885HTR2C 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.